HLTH - Cue Health wins FDA emergency nod for mpox test

2023-03-20 12:31:25 ET

• San Diego, CA-based diagnostics company Cue Health ( NASDAQ: HLTH ) announced Monday that the FDA issued Emergency Use Authorization for a molecular test to detect the mpox virus, formerly identified as monkeypox.
• The nucleic acid amplification test is the company's first non-COVID test to receive FDA authorization.
• It can be performed at any CLIA-waived lab facility using a Cue Sample Wand, Cue Cartridge, and Cue Reader, with results delivered to a mobile device in 25 minutes.
• "The FDA EUA for our Mpox Molecular Test provides a great tool for clinicians and their patients and demonstrates our platform's versatility," the chief executive of Cue Health ( HLTH ), Ayub Khattak, remarked.
• Early this year, Seeking Alpha contributor Samuel Petersson warned that HLTH is at risk of running out of cash in two years if operating expenses continue to rise.

For further details see: